Proteolytic cleavage of carboxypeptidase N markedly increases its antifibrinolytic activity

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 5, 2008, Pages 848-855

  Walker, J B ^a   Binette, T M ^a   Mackova, M ^a   Lambkin, G R ^a   Mitchell, L ^a   Bajzar, Laszlo ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Activation; Antifibrinolytic; Brinolysis; Carboxypeptidase N; Plasmin; Threshold

Indexed keywords

ARGININE CARBOXYPEPTIDASE; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTROPHORESIS; ENZYME ACTIVITY; ENZYME ISOLATION; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION;

ANTIFIBRINOLYTIC AGENTS; DIMERIZATION; FIBRINOLYSIS; HUMANS; LYSINE CARBOXYPEPTIDASE; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 42149106757     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.02912.x     Document Type: Article

References (48)

1. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
2. Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989; 162: 933-9.
3. Hendriks D, Wang W, Van SM, Scharpe S. Human serum carboxypeptidase U: A new kininase? Agents Actions Suppl 1992; 38 (Pt 1): 407-13.
4. Erdos EG, Sloane EM. An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem Pharmacol 1962; 11: 585-92.
5. Plummer TH Jr, Hurwitz MY. Human plasma carboxypeptidase N. Isolation and characterization. J Biol Chem 1978; 253: 3907-12.
6. Levin Y, Skidgel RA, Erdos EG. Isolation and characterization of the subunits of human plasma carboxypeptidase N (kininase I). Proc Natl Acad Sci U S A 1982; 79: 4618-22.
7. Skidgel RA, Kawahara MS, Hugli TE. Functional significance of the subunits of carboxypeptidase N (kininase I). Adv Exp Med Biol 1986; 198 (Pt A): 375-80.
8. Skidgel RA. Human carboxypeptidase N: Lysine carboxypeptidase. Methods Enzymol 1995; 248: 653-63.
9. Reznik SE, Fricker LD. Carboxypeptidases from A to z: Implications in embryonic development and Wnt binding. Cell Mol Life Sci 2001; 58: 1790-804.
10. Matthews KW, Mueller-Ortiz SL, Wetsel RA. Carboxypeptidase N: A pleiotropic regulator of inflammation. Mol Immunol 2004; 40: 785-93.
11. Quagraine MO, Tan F, Tamei H, Erdos EG, Skidgel RA. Plasmin alters the activity and quaternary structure of human plasma carboxypeptidase N. Biochem J 2005; 388: 81-91.
12. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-100.
13. Mosnier LO, Von dem Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
14. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
15. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
16. Mao SS, Cooper CM, Wood T, Shafer JA, Gardell SJ. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. J Biol Chem 1999; 274: 35046-52.
17. Marx PF, Dawson PE, Bouma BN, Meijers JC. Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry 2002; 41: 6688-96.
18. Mathews KP, Pan PM, Gardner NJ, Hugli TE. Familial carboxypeptidase N deficiency. Ann Intern Med 1980; 93: 443-5.
19. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 1994; 269: 21191-7.
20. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem 1994; 269: 21198-203.
21. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
22. Fogg DK, Bridges DE, Cheung KK, Kassam G, Filipenko NR, Choi KS, Fitzpatrick SL, Nesheim M, Waisman DM. The p11 subunit of annexin II heterotetramer is regulated by basic carboxypeptidase. Biochemistry 2002; 41: 4953-61.
23. Campbell WD, Lazoura E, Okada N, Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002; 46: 131-4.
24. Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, Pearl RG, Leung LL. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059-67.
25. Kwon M, MacLeod TJ, Zhang Y, Waisman DM. S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors. Front Biosci 2005; 10: 300-25.
26. Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circulation 1996; 93: 1328-30.
27. Swaisgood CM, Schmitt D, Eaton D, Plow EF. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest 2002; 110: 1275-82.
28. Walker JB, Bajzar L. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability. J Biol Chem 2004; 279: 27896-904.
29. Leurs J, Nerme V, Sim Y, Hendriks D. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism. J Thromb Haemost 2004; 2: 416-23.
30. Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry 1995; 34: 5811-6.
31. Boffa MB, Bell R, Stevens WK, Nesheim ME. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 2000; 275: 12868-78.
32. Marx PF, Hackeng TM, Dawson PE, Griffin JH, Meijers JC, Bouma BN. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J Biol Chem 2000; 275: 12410-5.
33. Walker JB, Hughes B, James I, Haddock P, Kluft C, Bajzar L. Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro. J Biol Chem 2003; 278: 8913-21.
34. Walker JB, Bajzar L. Complete inhibition of fibrinolysis by sustained carboxypeptidase B activity: The role and requirement of plasmin inhibitors. J Thromb Haemost 2007; 5: 1257-64.
35. Walker JB, Nesheim ME. The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J Biol Chem 1999; 274: 5201-12.
36. Wiman B. Affinity-chromatographic purification of human alpha 2-antiplasmin. Biochem J 1980; 191: 229-32.
37. Barenholz Y, Gibbes D, Litman BJ, Goll J, Thompson TE, Carlson RD. A simple method for the preparation of homogeneous phospholipid vesicles. Biochemistry 1977; 16: 2806-10.
38. Davis BJ. Disc electrophoresis. II. Method and application to human serum proteins. Ann N Y Acad Sci 1964; 121: 404-27.
39. Neville DM Jr. Molecular weight determination of protein-dodecyl sulfate complexes by gel electrophoresis in a discontinuous buffer system. J Biol Chem 1971; 246: 6328-34.
40. Leurs J, Wissing BM, Nerme V, Schatteman K, Bjorquist P, Hendriks D. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma. Thromb Haemost 2003; 89: 264-71.
41. Miles LA, Levin EG, Plescia J, Collen D, Plow EF. Plasminogen receptors, urokinase receptors, and their modulation on human endothelial cells. Blood 1988; 72: 628-35.
42. Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surfaces: Evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986; 103: 2411-20.
43. Delk AS, Durie PR, Fletcher TS, Largman C. Radioimmunoassay of active pancreatic enzymes in sera from patients with acute pancreatitis. I. Active carboxypeptidase B. Clin Chem 1985; 31: 1294-300.
44. Borgstrom A, Regner S. Active carboxypeptidase B is present in free form in serum from patients with acute pancreatitis. Pancreatology 2005; 5: 530-6.
45. Pitchumoni CS, Agarwal N, Jain NK. Systemic complications of acute pancreatitis. Am J Gastroenterol 1988; 83: 597-606.
46. Campo SM, Gasparri V, Catarinelli G, Sepe M. Acute pancreatitis with Purtscher's retinopathy: Case report and review of the literature. Dig Liver Dis 2000; 32: 729-32.
47. Mendelson RM, Anderson J, Marshall M, Ramsay D. Vascular complications of pancreatitis. ANZ J Surg 2005; 75: 1073-9.
48. Ritchie BC. Protease inhibitors in the treatment of hereditary angioedema. Transfus Apher Sci 2003; 29: 259-67.